Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695394 | 0.94 | CACNA2D1 (0.52) | CDK1CACNA2D1ADRA1DCHRM2CHRM4 | |
| SCHEMBL706212 | 0.87 | CDK1 (0.52) | CDK1CACNA2D1ADRA1DLMNACHRM2 | |
| SCHEMBL710054 | 0.86 | CDK1 (0.67) | CDK1ADRA1DLMNACHRM2CHRM4 | |
| SCHEMBL4956877 | 0.86 | CDK1 (0.52) | CDK1ADRA1DLMNACHRM2CHRM4 | |
| SCHEMBL708875 | 0.80 | KDM4E (0.44) | CDK1CACNA2D1ADRA1DLMNACHRM2 | |
| SCHEMBL29510791 | 0.80 | KDM4E (0.44) | CDK1CACNA2D1ADRA1DLMNACHRM2 | |
| SCHEMBL5305381 | 0.80 | CACNA2D1 (0.46) | CDK1CACNA2D1ADRA1DLMNACHRM2 | |
| SCHEMBL710488 | 0.80 | KDM4E (0.58) | CDK1ADRA1DLMNACHRM2CHRM4 | |
| SCHEMBL4745453 | 0.80 | KDM4E (0.43) | CDK1CACNA2D1ADRA1DLMNACHRM2 | |
| SCHEMBL29510895 | 0.80 | KDM4E (0.58) | CDK1ADRA1DLMNACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | claimed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | claimed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260007766-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2026-01-08 | — | — | US | disclosed |
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250381285-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12491257-B2 | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates | AVIDITY BIOSCIENCES, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4656242-A2 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4126066-B1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | KOSAK KENNETH M | 2008-02-28 | — | — | US | disclosed |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | KOSAK KENNETH M | 2007-07-19 | — | — | US | disclosed |
| WO-2007040469-A2 | CHLOROQUINE COUPLED COMPOSITIONS AND METHODS FOR THEIR SYNTHESIS | KOSAK KEN M (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | KOSAK KENNETH M | 2007-03-15 | — | — | US | disclosed |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | KOSAK KENNETH M | 2006-02-23 | — | — | US | disclosed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | disclosed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | CDK1 4003/4885CACNA2D1 3822/4885ADRA1D 4481/4885 |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | MYLK2, PRKCG, PRKAG2 | CDK1 3379/4885CACNA2D1 3448/4885ADRA1D 2212/4885 |
| US-20250381285-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, PYGM, MYOF | CDK1 1420/4885CACNA2D1 3751/4885ADRA1D 1272/4885 |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | GPR119, CLTA, CHMP4B | CDK1 2387/4885CACNA2D1 4063/4885ADRA1D 4294/4885 |
| US-12491257-B2 | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates | PRKCG, PRKAG2, PRKAG1 | CDK1 3087/4885CACNA2D1 3969/4885ADRA1D 3418/4885 |
| US-20260007766-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | MYOF, MTPN, TTN | CDK1 3367/4885CACNA2D1 2375/4885ADRA1D 1650/4885 |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | CHMP4B, CTSA, CLTA | CDK1 1812/4885CACNA2D1 4333/4885ADRA1D 4407/4885 |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | CHMP4B, CTSA, CLTA | CDK1 1791/4885CACNA2D1 4508/4885ADRA1D 4550/4885 |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | TLR9, TLR3, EXOSC5 | CDK1 2413/4885CACNA2D1 4634/4885ADRA1D 4577/4885 |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | UPF1, MYOF, MTPN | CDK1 4328/4885CACNA2D1 2330/4885ADRA1D 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.